
SUMMARY


In an aspect of the present disclosure, there is provided a use of a compound of the formula:



,

or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of a neurodegenerative disease, wherein a total dose of 0.1 mg/day to 5 mg/day of the compound, or pharmaceutically acceptable salt thereof is to be administered orally


In another aspect of the present disclosure, there is provided a use of a compound of the formula:



,

or a pharmaceutically acceptable salt thereof, for in the manufacture of a medicament for preventing the progression of mild cognitive impairment to Alzheimer's disease wherein a total dose of 0.1 mg/day to 5 mg/day of the compound, or pharmaceutically acceptable salt thereof is to be administered orally.

In a further aspect of the present disclosure, there is provided a pharmaceutical composition, comprising a compound of the formula:




,

or a pharmaceutically acceptable salt thereof with one or more pharmaceutically acceptable carriers, diluents, or excipients wherein the pharmaceutical composition contains a total dose of the compound of 0.1 mg to 5 mg.

DESCRIPTION

Accordingly, in one embodiment, the invention provides a compound of Formula I:




Formula I

,

or a pharmaceutically acceptable salt thereof, for use in treating a neurodegenerative disease wherein the compound, or pharmaceutically acceptable salt thereof is administered orally with a total dose of the compound of 0.1 mg/day to 5 mg/day.

In an embodiment, the invention provides a compound of Formula I:




Formula I

,

or a pharmaceutically acceptable salt thereof, wherein the compound, or pharmaceutically acceptable salt thereof is administered orally with a total dose of the compound of 0.1 mg/day to 5 mg/day for use in treating Alzheimer's disease.

In an embodiment, the invention provides a compound of Formula I:




Formula I

,

or a pharmaceutically acceptable salt thereof, wherein the compound, or pharmaceutically acceptable salt thereof is administered orally with a total dose of the compound of 0.1 mg/day to 5 mg/day for use in treating progressive supranuclear palsy.

In an embodiment, the invention provides a compound of Formula I:




Formula I

,

WHAT IS CLAIMED IS:

1. Use of a compound of the formula:




,

or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of a neurodegenerative disease, wherein a total dose of 0.1 mg/day to 5 mg/day of the compound, or pharmaceutically acceptable salt thereof is to be administered orally.

2. The use according to claim 1 wherein the neurodegenerative disease is Alzheimer's disease.

3. The use according to claim 1 wherein the neurodegenerative disease is progressive supranuclear palsy.

4. Use of a compound of the formula:




,

or a pharmaceutically acceptable salt thereof, for in the manufacture of a medicament for preventing the progression of mild cognitive impairment to Alzheimer's disease wherein a total dose of 0.1 mg/day to 5 mg/day of the compound, or pharmaceutically acceptable salt thereof is to be administered orally.

5. The use according to any one of claims 1 to 4 wherein the total dose of the compound is 0.25 mg/day to 5 mg/day, or 0.1 mg/day to 3 mg/day, or 0.25 mg/day to 3 mg/day, or 0.1 mg/day to 2 mg/day, or 0.25 mg/day to 2 mg/day, or 0.1 mg/day to 1 mg/day, or 0.25 mg/day to 1 mg/day.

6. The use according to any one of claims 1 to 4 wherein the total dose of the compound is 3 mg/day, or 2.5 mg/day, or 2 mg/day, or 1.5 mg/day, or 1 mg/day, or 0.75 mg/day, or 0.5 mg/day, or 0.25 mg/day.

7. The use according to any one of claims 1 to 6 wherein the compound or pharmaceutically acceptable salt thereof is to be administered in unit dosage form.
8. The use according to claim 7 wherein the unit dosage form is selected from a capsule, tablet, gelcap, liquid solution, and liquid suspension.
9. The use according to claim 8 wherein the unit dosage form is a capsule or a tablet.
10. The use according to any one of claims 7-9 wherein the total daily dose is to be administered in one unit dose.
11. The use according to any one of claims 7-9 wherein the total daily dose is to be administered in two unit doses.
12. The use according to claim 11 wherein the administration of each unit dose is separated by at least 8 hours.
13. A pharmaceutical composition, comprising a compound of the formula:



,

or a pharmaceutically acceptable salt thereof with one or more pharmaceutically acceptable carriers, diluents, or excipients wherein the pharmaceutical composition contains a total dose of the compound of 0.1 mg to 5 mg.

14. The pharmaceutical composition according to claim 13 wherein the total dose of the compound is 0.25 mg to 5 mg, or 0.1 mg to 3 mg, or 0.25 mg to 3 mg, or 0.1 mg to 2 mg, or 0.25 mg to 2 mg, or 0.1 mg to 1 mg, or 0.25 mg to 1 mg.
15. The pharmaceutical composition according to claim 13 wherein the total dose of the compound is 3 mg, or 2.5 mg, or 2 mg, or 1.5 mg, or 1 mg, or 0.75 mg, or 0.5 mg, or 0.25 mg.
16. The pharmaceutical composition according to any one of claims 13 to 15 wherein the total dose of the compound is contained in one unit dose.

17. The pharmaceutical composition according to any one of claims 13 to 15 wherein the total dose of the compound is contained in two unit doses.
18. The pharmaceutical composition according to any one of claims 13 to 15 wherein the total dose of the compound is contained in two unit doses with each unit dose containing equal amounts of the compound.